Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 11 h ago

Aktis Oncology, Inc.: T. Rowe Price Investment Management, Inc. discloses a stake of more than 5% (Schedule 13G)

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

T. Rowe Price Investment Management disclosed a stake exceeding 5% in Aktis Oncology in a Schedule 13G filing with the SEC (accession 0001897612-26-000760). The exact share count and percentage were not specified in the headline disclosure. The filing signals active institutional ownership in the oncology company and typically precedes further engagement or position changes. Investors will watch for subsequent 13G amendments for precise holdings and any shifts in the position.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

T. Rowe Price Investment Management, Inc., Aktis Oncology, Inc.